Canada Allergy Immunotherapy Market Size & Outlook

The allergy immunotherapy market in Canada is expected to reach a projected revenue of US$ 57.8 million by 2027. A compound annual growth rate of 8.4% is expected of Canada allergy immunotherapy market from 2020 to 2027.
Revenue, 2019 (US$M)
$30.3
Forecast, 2027 (US$M)
$57.8
CAGR, 2020 - 2027
8.4%
Report Coverage
Canada

Canada allergy immunotherapy market highlights

  • The Canada allergy immunotherapy market generated a revenue of USD 30.3 million in 2019 and is expected to reach USD 57.8 million by 2027.
  • The Canada market is expected to grow at a CAGR of 8.4% from 2020 to 2027.
  • In terms of segment, subcutaneous immunotherapy was the largest revenue generating treatment type in 2019.
  • Sublingual immunotherapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.


Allergy immunotherapy market data book summary

Market revenue in 2019USD 30.3 million
Market revenue in 2027USD 57.8 million
Growth rate8.4% (CAGR from 2019 to 2027)
Largest segmentSubcutaneous immunotherapy
Fastest growing segmentSublingual immunotherapy
Historical data2016 - 2018
Base year2019
Forecast period2020 - 2027
Quantitative unitsRevenue in USD million
Market segmentationSubcutaneous immunotherapy, Sublingual immunotherapy
Key market players worldwideMerck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer


Other key industry trends

  • In terms of revenue, Canada accounted for 1.9% of the global allergy immunotherapy market in 2019.
  • Country-wise, Germany is expected to lead the global market in terms of revenue in 2027.
  • In North America, U.S. allergy immunotherapy market is projected to lead the regional market in terms of revenue in 2027.
  • U.S. is the fastest growing regional market in North America and is projected to reach USD 631.7 million by 2027.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Allergy Immunotherapy Market Companies

Name Profile # Employees HQ Website

Canada allergy immunotherapy market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.


Subcutaneous immunotherapy was the largest segment with a revenue share of 84.16% in 2019. Horizon Databook has segmented the Canada allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.


Allergic rhinitis affects nearly 20% to 25% of the Canadian population. In addition, 50% of the affected population cannot be cured by the use of conventional symptomatic medications. Therefore, key players are focused on the launch of innovative immunotherapy products in Canada.

For instance, ALK submitted application for the Canadian regulatory filing of its investigational tree pollen SLIT tablet in 2019. The review was accepted by the authorities in June 2019. The tablet is indicated for respiratory allergies caused due to allergens from birch, beech, alder, oak, and hazel trees.

Reasons to subscribe to Canada allergy immunotherapy market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Canada allergy immunotherapy market databook

  • Our clientele includes a mix of allergy immunotherapy market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada allergy immunotherapy market, including forecasts for subscribers. This country databook contains high-level insights into Canada allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Canada allergy immunotherapy market size, by treatment type, 2016-2027 (US$M)

Canada Allergy Immunotherapy Market Share, 2019 & 2027 (US$M)

Canada allergy immunotherapy market size, by treatment type, 2016-2027 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more